Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPA-201 in Relapsed, Refractory Multiple Myeloma
NCT04176380Phase 2Completed
- Sponsor
- Rapa Therapeutics
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
Phase 2, open-label trial of rapa-201 in multiple myeloma (MM), sponsored by Rapa Therapeutics. Primary endpoint: Overall Response Rate at 1 year. Started Dec 2020; status: completed.
02
Drugs
rapa-201
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04176380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176380.